US009284280B2

(12) **United States Patent**
Itou

(10) **Patent No.: US 9,284,280 B2**
(45) **Date of Patent: Mar. 15, 2016**

(54) **USE OF FORM-I CRYSTAL OF 2-{4-[N-(5,6-DIPHENYLPYRAZIN-2-YL)-N-ISOPROPYL-AMINO]BUTYLOXY}-N-(METHYL-SULFONYL)ACETAMIDE**

(71) Applicant: **Hideyuki Itou**, Kyoto (JP)

(72) Inventor: **Hideyuki Itou**, Kyoto (JP)

(73) Assignee: **NIPPON SHINYAKU CO., LTD.**, Kyoto (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/160,641**

(22) Filed: **Jan. 22, 2014**

(65) **Prior Publication Data**

US 2014/0148469 A1 May 29, 2014

Related U.S. Application Data

(63) Continuation of application No. 13/379,531, filed as application No. PCT/JP2010/060798 on Jun. 25, 2010, now Pat. No. 8,791,122.

(30) **Foreign Application Priority Data**

Jun. 26, 2009 (JP) 2009-151727
Jun. 26, 2009 (JP) 2009-151728
Jun. 26, 2009 (JP) 2009-151729

(51) **Int. Cl.**
C07D 241/02 (2006.01)
C07D 241/20 (2006.01)
A61K 31/4965 (2006.01)

(52) **U.S. Cl.**
CPC ***C07D 241/20*** (2013.01); ***A61K 31/4965*** (2013.01); *C07B 2200/13* (2013.01)

(58) **Field of Classification Search**
CPC C07D 233/60; C07D 241/20
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,394,793	B2	3/2013	Kyoi
8,575,175	B2	11/2013	Matsuda et al.
8,629,145	B2	1/2014	Kuwano
8,729,086	B2	5/2014	Murakami et al.
8,889,693	B2	11/2014	Murakami et al.
2003/0092760	A1	5/2003	Kurumatani et al.
2004/0102436	A1	5/2004	Asaki et al.
2004/0116530	A1	6/2004	Maeda et al.
2006/0189695	A1	8/2006	Uchida et al.
2011/0015211	A1	1/2011	Murakami et al.
2011/0098481	A1	4/2011	Murata et al.
2011/0105518	A1	5/2011	Kuwano
2011/0118254	A1	5/2011	Kyoi
2011/0178103	A1	7/2011	Matsuda et al.
2014/0221397	A1	8/2014	Murakami et al.

FOREIGN PATENT DOCUMENTS

EP	1 106 176	A1	6/2001
EP	1400518	A1	3/2004
EP	1 642 584	A1	4/2006
EP	2 246 336	A1	11/2010
EP	2 289 518	A1	3/2011
EP	2 292 231	A1	3/2011
EP	2 343 292	A1	7/2011
WO	02/088084	A1	11/2002
WO	2009/107736	A1	9/2009
WO	2009/154246	A1	12/2009
WO	2009/157396	A1	12/2009
WO	2009/157397	A1	12/2009
WO	2009/157398	A1	12/2009

OTHER PUBLICATIONS

J. Keith Guillory, "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids," Polymorphism in Pharmaceutical Solids, pp. 183-226, Marcel Dekker, Inc., New York (1999).
Mino R. Caira, "Crystalline Polymorphism of Organic Compounds," Topics in Current Chemistry, vol. 198, pp. 163-208 (1998).
Vippagunta, et al., "Crystalline Solids," Advanced Drug Delivery Reviews, vol. 48, pp. 3-26, (2001).
Morissette, et al., "High-Throughput Crystallization: Polymorphs, Salts, Co-Crystals and Solvates of Pharmaceutical Solids," Advanced Drug Delivery Reviews, vol. 56, pp. 275-300, (2004).
Byrn, et al., "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations," Pharmaceutical Research, vol. 12, No. 7, pp. 945-954 (1995).
David J.W. Grant, "Theory and Origin of Polymorphism," Polymorphism in Pharmaceutical Solids, pp. 1-10, Marcel Dekker, Inc., New York (1999).
Gennaro, "Remington: The Science and Practice of Pharmacy," 19th Edition, Second Volume, Lippincott Williams & Wilkins, (1995).
(Continued)

Primary Examiner — Michael Barker
Assistant Examiner — Karen Cheng

(57) **ABSTRACT**

A method is provided in which Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is administered as an active ingredient to a subject for the purpose of treating or preventing certain diseases, disorders, and symptoms, or for promoting angiogenesis or gene therapy. The Form-I crystal exhibits diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ when the spectrum is obtained by using Cu Kα radiation: 9.4 degrees, 9.8 degrees, 17.2 degrees, and 19.4 degrees. The targeted diseases and disorders include transient ischemic attack, diabetic neuropathy, diabetic gangrene, peripheral circulatory disturbance, connective tissue disease, reocclusion/restenosis after percutaneous transluminal coronary angioplasty, arteriosclerosis, thrombosis, hypertension, pulmonary hypertension, ischemic disorder, angina, glomerulonephritis, diabetic nephropathy, chronic renal failure, allergy, bronchial asthma, ulcer, pressure ulcer (bedsore), restenosis after coronary intervention, thrombocytopenia by dialysis, the diseases in which fibrosis of organs or tissues is involved, erectile dysfunction, inflammatory bowel disease, and gastritis.

9 Claims, 6 Drawing Sheets